Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Mirati Therapeutics, Inc. is a targeted oncology company developing a pipeline of therapeutics for precisely defined patient populations. The Mirati team is using a blueprint proven by their prior work for developing potential breakthrough therapies with accelerated development paths.
Website: mirati.com


  • Good financial results growth rate 100.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (47.5%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield -28.8% (LTM)
  • Share price is 111.2% higher than minimum and 5.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (500.0x vs 30.0x)

Key Financials (Download financials)

Ticker: MRTX
Share price, USD:  (0.0%)58.7
year average price 58.70  


year start price 58.70 2024-12-25

max close price 58.70 2024-12-25

min close price 58.70 2024-12-25

current price 58.70 2025-12-24
Common stocks: 56 219 000

Dividend Yield:  0.0%
EV / Sales: 81.4x
Margin (EBITDA LTM / Revenue): -2 007.9%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 3 300
Net Debt ($m): -208
EV (Enterprise Value): 3 092
EBITDA LTM (млн $): -763
Price to Book: 3.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2024-04-05Finbold

How this insider trader nailed every single stock trade

2024-01-11Zacks Investment Research

Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC

2023-12-06Zacks Investment Research

Mirati (MRTX) Up 1.1% Since Last Earnings Report: Can It Continue?

2023-11-10Reuters

Mirati's lung cancer drug gets EU's regulatory backing

2023-11-07Zacks Investment Research

Mirati's (MRTX) Q3 Loss Narrows, Sales Miss Expectations

2023-10-09Schaeffers Research

Analysts Target Biotech Name on Buyout Buzz

2023-10-08Reuters

Bristol-Myers Squibb to acquire Mirati in a $4.8 billion deal

2023-10-06Zacks Investment Research

Mirati (MRTX) Surges 45% as Sanofi Reportedly Eyes Buyout

2023-09-22Zacks Investment Research

Mirati (MRTX) Soars 12.3%: Is Further Upside Left in the Stock?

2023-08-09Zacks Investment Research

Mirati (MRTX) Q2 Earnings Beat, Stock Up on Solid Krazati Sales
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24
calendarYear 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3
revenue 16M 14M 7M 934 000 5M
costOfRevenue 2M 1M 817 000 600 000 0
grossProfit 14M 12M 6M 334 000 5M
grossProfitRatio 0.845 0.906 0.886 0.358 1
researchAndDevelopmentExpenses 115M 124M 127M 141M 131M
generalAndAdministrativeExpenses 0 0 0 169M 61M
sellingAndMarketingExpenses 0 0 0 -98M 0
sellingGeneralAndAdministrativeExpenses 72M 75M 73M 71M 61M
otherExpenses 259 000 258 000 9M 10M 0
operatingExpenses 187M 200M 200M 212M 192M
costAndExpenses 188M 201M 201M 213M 192M
interestIncome 0 0 0 0 0
interestExpense 0 0 -3M -6M -13M
depreciationAndAmortization 1M 1M 1M 891 000 716 000
ebitda -171M -186M -194M -212M -186M
ebitdaratio -10.423 -13.598 -27.044 -226.684 -34.198
operatingIncome -172M -187M -194M -212M -186M
operatingIncomeRatio -10.491 -13.679 -27.044 -226.684 -34.329
totalOtherIncomeExpensesNet 10M 10M 9M 10M 13M
incomeBeforeTax -162M -177M -185M -202M -173M
incomeBeforeTaxRatio -9.872 -12.923 -25.755 -216.511 -31.911
incomeTaxExpense 0 0 -9M 254 000 254 000
netIncome -162M -177M -175M -202M -174M
netIncomeRatio -9.872 -12.923 -24.466 -216.783 -31.957
eps -2.49 -3.04 -3.02 -3.51 -3.09
epsdiluted -2.49 -3.04 -3.02 -3.51 -3.09
weightedAverageShsOut 65M 58M 58M 58M 56M
weightedAverageShsOutDil 65M 58M 58M 58M 56M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24
calendarYear 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 259M 130M 242M 235M 299M
shortTermInvestments 718M 650M 660M 849M 902M
cashAndShortTermInvestments 976M 779M 902M 1 084M 1 201M
netReceivables 20M 16M 6M 865 000 2M
inventory 20M 9M 4M 3M 0
otherCurrentAssets 19M 15M 27M 21M 23M
totalCurrentAssets 1 036M 819M 939M 1 109M 1 226M
propertyPlantEquipmentNet 51M 52M 53M 54M 54M
goodwill 0 0 0 0 0
intangibleAssets 14M 14M 15M 15M 0
goodwillAndIntangibleAssets 14M 14M 15M 15M 0
longTermInvestments 4M 5M 3M 3M 2M
taxAssets 24M 24M 0 0 0
otherNonCurrentAssets 620 000 620 000 23M 22M 21M
totalNonCurrentAssets 94M 96M 94M 94M 77M
otherAssets 0 0 0 0 0
totalAssets 1 130M 915M 1 034M 1 203M 1 303M
accountPayables 38M 33M 22M 39M 19M
shortTermDebt 8M 8M 8M 8M 7M
taxPayables 0 0 0 0 0
deferredRevenue -8M -8M 0 0 0
otherCurrentLiabilities 91M 100M 94M 113M 100M
totalCurrentLiabilities 137M 140M 125M 159M 127M
longTermDebt 0 0 43M 44M 44M
deferredRevenueNonCurrent 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0
otherNonCurrentLiabilities 46M 46M 3M 3M 20M
totalNonCurrentLiabilities 46M 46M 47M 47M 47M
otherLiabilities 0 0 0 0 0
capitalLeaseObligations 0 0 43M 44M 51M
totalLiabilities 183M 186M 171M 206M 174M
preferredStock 0 0 0 0 0
commonStock 70 000 58 000 58 000 58 000 58 000
retainedEarnings -2 976M -2 814M -2 637M -2 453M -2 250M
accumulatedOtherComprehensiveIncomeLoss -2M -2M -2M -4M -6M
othertotalStockholdersEquity 3 924M 3 545M 3 502M 3 453M 3 386M
totalStockholdersEquity 946M 729M 863M 997M 1 129M
totalEquity 946M 729M 863M 997M 1 129M
totalLiabilitiesAndStockholdersEquity 1 130M 915M 1 034M 1 203M 1 303M
minorityInterest 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 130M 915M 1 034M 1 203M 1 303M
totalInvestments 718M 654M 660M 849M 904M
totalDebt 50M 51M 43M 52M 51M
netDebt -208M -79M -199M -184M -248M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol MRTX MRTX MRTX MRTX MRTX
reportedCurrency USD USD USD USD USD
cik 2M 2M 2M 2M 2M
fillingDate 2023-11-06 2023-08-08 2023-05-09 2023-02-28 2022-11-08
acceptedDate 2023-11-06 07:08:36 2023-08-08 16:02:56 2023-05-09 16:22:07 2023-02-28 16:26:14 2022-11-08 16:32:24
calendarYear 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3
netIncome -162M -177M -185M -202M -174M
depreciationAndAmortization 1M 1M 1M 891 000 716 000
deferredIncomeTax -122M -144M 0 0 0
stockBasedCompensation 45M 39M 47M 62M 43M
changeInWorkingCapital -23M 12M -49M 17M 2M
accountsReceivables -4M -4M -5M -865 000 0
inventory -12M -5M -829 000 -3M 0
accountsPayables 0 0 -35M -5M 0
otherWorkingCapital -7M 21M 41M 26M 0
otherNonCashItems 117M 138M -5M -6M -10M
netCashProvidedByOperatingActivities -144M -131M -190M -129M -138M
investmentsInPropertyPlantAndEquipment -36 000 -722 000 -269 000 -810 000 -1M
acquisitionsNet 62M -16M 0 0 0
purchasesOfInvestments -342M -237M -127M -237M -378M
salesMaturitiesOfInvestments 280M 253M 322M 297M 393M
otherInvestingActivites -62M 16M 0 0 0
netCashUsedForInvestingActivites -62M 16M 195M 59M 14M
debtRepayment 0 0 0 0 0
commonStockIssued 329M 3M 2M 155M 0
commonStockRepurchased 0 0 0 0 0
dividendsPaid 0 0 0 0 0
otherFinancingActivites 335M 4M 0 -149M 157M
netCashUsedProvidedByFinancingActivities 335M 4M 2M 6M 157M
effectOfForexChangesOnCash 59 000 -34 000 -31 000 0 0
netChangeInCash 129M -112M 7M -64M 33M
cashAtEndOfPeriod 259M 130M 243M 236M 299M
cashAtBeginningOfPeriod 130M 243M 236M 299M 266M
operatingCashFlow -144M -131M -190M -129M -138M
capitalExpenditure -36 000 -722 000 -269 000 -810 000 -1M
freeCashFlow -144M -132M -190M -130M -139M
link Link Link Link Link Link
finalLink Link Link Link Link Link

Earning call transcript

2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2023-11-06 08:05 ET
Mirati Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 07:08 ET
Mirati Therapeutics reported for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Mirati Therapeutics reported for 2023 q3
SEC form 6
2023-08-09 16:40 ET
Mirati Therapeutics published news for 2023 q2
SEC form 10
2023-08-08 16:02 ET
Mirati Therapeutics reported for 2023 q2
SEC form 6
2023-08-08 16:01 ET
Mirati Therapeutics reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Mirati Therapeutics reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Mirati Therapeutics reported for 2023 q2
SEC form 6
2023-07-21 06:05 ET
Mirati Therapeutics published news for 2023 q2
SEC form 6
2023-06-23 17:16 ET
Mirati Therapeutics published news for 2023 q1
SEC form 6
2023-06-23 16:02 ET
Mirati Therapeutics published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Mirati Therapeutics reported for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Mirati Therapeutics reported for 2023 q1
SEC form 10
2023-02-28 16:26 ET
Mirati Therapeutics reported for 2022 q4
SEC form 6
2023-02-28 16:08 ET
Mirati Therapeutics reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Mirati Therapeutics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Mirati Therapeutics reported for 2022 q4
SEC form 6
2023-01-24 16:20 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:19 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:17 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:03 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-24 16:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-20 09:20 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2023-01-09 13:06 ET
Mirati Therapeutics published news for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Mirati Therapeutics published news for 2022 q4
SEC form 6
2022-12-21 21:20 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-21 21:20 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-12 20:22 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-05 19:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-05 17:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-12-02 08:01 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-11-28 19:01 ET
Mirati Therapeutics published news for 2022 q3
SEC form 6
2022-11-08 18:00 ET
Mirati Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 16:32 ET
Mirati Therapeutics reported for 2022 q3
SEC form 6
2022-11-08 16:23 ET
Mirati Therapeutics published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Mirati Therapeutics reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Mirati Therapeutics reported for 2022 q3
SEC form 6
2022-09-08 06:08 ET
Mirati Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 16:07 ET
Mirati Therapeutics reported for 2022 q2
SEC form 6
2022-08-03 16:04 ET
Mirati Therapeutics published news for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Mirati Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Mirati Therapeutics reported for 2022 q2
SEC form 6
2022-06-14 16:35 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-06-07 08:06 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-06-06 08:07 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-26 17:06 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 17:01 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-16 16:42 ET
Mirati Therapeutics published news for 2022 q1
SEC form 6
2022-05-12 17:07 ET
Mirati Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 16:22 ET
Mirati Therapeutics reported for 2022 q1
SEC form 6
2022-05-04 16:10 ET
Mirati Therapeutics reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Mirati Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Mirati Therapeutics reported for 2022 q1
SEC form 6
2022-04-15 16:26 ET
Mirati Therapeutics published news for 2022 q1
SEC form 10
2022-02-28 16:20 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-02-28 16:06 ET
Mirati Therapeutics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Mirati Therapeutics published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-02-15 16:16 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2022-01-10 10:55 ET
Mirati Therapeutics published news for 2021 q4
SEC form 6
2021-11-12 06:16 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-09 16:24 ET
Mirati Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 16:25 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-08 16:08 ET
Mirati Therapeutics published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Mirati Therapeutics published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-11-01 07:32 ET
Mirati Therapeutics published news for 2021 q3
SEC form 6
2021-09-24 17:10 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-09-20 08:10 ET
Mirati Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 16:42 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-08-05 16:34 ET
Mirati Therapeutics published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Mirati Therapeutics published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-07-02 16:04 ET
Mirati Therapeutics published news for 2021 q2
SEC form 6
2021-06-28 17:02 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-06-01 08:41 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-05-12 16:21 ET
Mirati Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 16:37 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-05-06 16:28 ET
Mirati Therapeutics published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Mirati Therapeutics published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-04-16 16:26 ET
Mirati Therapeutics published news for 2021 q1
SEC form 6
2021-03-30 17:41 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-03-30 17:09 ET
Mirati Therapeutics published news for 2020 q4
SEC form 10
2021-02-25 16:37 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-02-25 16:31 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-01-11 07:31 ET
Mirati Therapeutics published news for 2020 q4
SEC form 6
2021-01-08 19:57 ET
Mirati Therapeutics published news for 2020 q4
SEC form 10
2020-11-04 16:47 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-11-04 16:36 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 16:38 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 16:53 ET
Mirati Therapeutics published news for 2020 q3
SEC form 6
2020-10-26 08:00 ET
Mirati Therapeutics published news for 2020 q3